DelveInsight Blogs Sitemap

All Posts in this category
S.No. Product Name Actions
1 FDA’s New Drug Application to ALS Drug; Approval to BeiGene’s Brukinsa; Roche, Temedica Forges Digital Companionship, Shares of Sage Therapeutics Rises Visit Post
2 Ascendis's SKYTROFA; MicroTransponder’s VNS System (Vivistim); BioMarin's Voxzogo; Zimmer-Canary's Smart Knee Implant; COVID-19 impact on Solid Organ Transplants Visit Post
3 Sanofi bets $3.2B on mRNA; Marinus signs $30M deal with Orion; Mestag with $45M seed; Moderna secures fast track designation Visit Post
4 Amgen acquires Teneobio for $2.5B; Signifier scores $35M; Biogen-Ionis’ drug meets a goal; AbbVie hits go on $1B re-upped Calico deal Visit Post
5 MedTech Market Industry: Approval of Devices, Therapy Address Market Needs | Clinical Outcomes Create New Value Visit Post
6 Insilico Medicine raises $255M; Sanofi & Translate Bio initiate trial; Medtronic gains expanded FDA approval; Blackstone, Cellex & Intellia form CAR-T startup Visit Post
7 Does the use of Assistive Technologies in Autism Spectrum Disorder Payoff? Visit Post
8 Mallinckrodt earns FDA nod for skin therapy; RayzeBio secures $108M; VectorY raises $38M; Umoja banks $210M Visit Post
9 Eclipse, Medtronic, Aethlon, Cognoa, ObvioHealth, and others Continue to Veer MedTech Market Forward Visit Post
10 Medical Devices Market Blooms as the Key MedTech Companies Continue to Bring-In Innovation Visit Post
11 Spinal Stenosis Devices Market Size to Balloon Up Owing to Increasing Prevalence & Geriatric Population, as well as Medical Advancements Visit Post
12 Migraine Market: How Pharma Companies are trying to Uncomplicate the Disease and Bring in Novel Therapies Visit Post
13 Biogen’s Alzheimer’s Drug; FDA approval to Novo Nordisk’s Wegovy; Bluebird's Gene Therapy Visit Post
14 MedTech Industry Roars Back as FDA Approvals Soar Visit Post
15 Arch Oncology scores $105M; Abbott’s new coronary imaging platform; Lilly scraps IL-23 psoriasis program; Biogen offer access to experimental ALS med Visit Post
16 Drug Development and Pipeline Analysis in the Alzheimer’s Disease Market Space Visit Post
17 How Depression Is Eroding The Mental And The Physical Health Of The Society? Visit Post
18 Bright Peak, Ajinomoto to Create Novel Immunocytokines; FDA’s Rejection to Lilly/Pfizer's Tanezumab for Osteoarthritis Pain; Ikena Oncology Unveils IPO Pricing Visit Post
19 Asher Bio raises $55M; Roche halts Huntington's phase 3 trial; Novartis' radioligand hits goal in phase 3; EpimAb raises $120M in Series C Visit Post
20 Which Pharma Companies are Transforming the Drug-Resistant Epilepsy Market Landscape? Visit Post
21 GBT strikes a deal with Sanofi; Lilly's IL-23 inhibitor shows promise; Glooko raises $30M; FDA uplifts hold on Solid’s DMD gene therapy Visit Post
22 Emerging Therapies in the Chronic Pain Pipeline Transforming the Chronic Pain Market Landscape Visit Post
23 Valo Health receives $110M Series B Cognito's therapy slows Alzheimer's disease Ventyx Biosciences raises $114M Takeda expands immuno-oncology portfolio Visit Post
24 Gene and Cell Therapies in CNS Disorders: Miracle Cure? Opportunities Galore! Visit Post
25 Bluebird suspends gene therapy trials; Cortexyme tripped up by FDA hold; Guardant Health launches surveillance blood test; Enhertu scores approval Visit Post
26 Merck, Eisai in renal cancer market; G1 Therapeutics on Cosela’s approval; Takeda's Maribavir; Astellas/Seagen Padcev Visit Post
27 Notorious Hyperkalemia: What are the causes, signs and new treatments? Visit Post
28 Eating Disorders: What Happens When Stigma And Misconceptions Command The Health Visit Post
29 The Burden And The Impact Of Mental Health Issues In Today’s Time Visit Post
30 Biohaven's Troriluzole Failure; Daiichi/ AZ's Enhertu; Fujifilm & Manufacturing Spree; J&J's Darzalex Faspro Visit Post
31 Parkinson's Disease: How close are we to a cure? Visit Post
32 Pfizer/ OPKO Health’s Somatrogon; FDA EU for SCONE device; Antengene ATG-010 for rrMM and rrDLBCL; SanBio STEMTRA Phase 2 Interim Results Visit Post
33 Watch Out For Top Pipeline Therapies Making An Impact In The Bipolar Depression Market Visit Post
34 21 of the most common questions about Epilepsy Visit Post
35 Mitochondria destruction for Cancer Treatment; Atsena raises USD 55 Million financings; Novartis and Cadent Therapeutics collaboration; Neuron23’s strategy to tackle CNS disorders Visit Post
36 Top Emerging Therapies To Watch Out for in the Retinal Vein Occlusion Market Visit Post
37 What are the options available for the treatment of Retinal vein occlusion? Visit Post
38 Santhera flunks DMD phase 3; Scribe emerges with $20 M; Merck sells off Osteoarthritis drug to Novartis; Research updates on flu vaccine and glioblastoma Visit Post
39 FDA rejects BioMarin's Valoctocogene Roxaparvovec; J&J inks $6.5B deal; Alzheon bags $47M; Research updates on diabetes Visit Post
40 Gilead's remdesivir trials; F2G raises $60.8M; Cancer immunotherapy research updates; Celleron gains rights to Roche's cancer drug Visit Post
41 MorphoSys, Incyte receive FDA Ok for Monjuvi; Siemens Healthineers set to buy Varian; Immunic's IMU-838 promising results Visit Post
42 Roche-UCB's $120M collaboration; Omega snags $85M; ExeVir raises $27M; GSK culls pipeline meds after failures Visit Post
43 Addressing The Scattered Harbingers of Frontotemporal Dementia Visit Post
44 Amylyx Raises $30M; QurAlis Announces License Agreement Deal With Lilly; COVID-19 Vaccine Updates; Researchers Develop a New Ultrafast Insulin Visit Post
45 Regeneron's I-O Drug; Gene Therapy for Parkinson's Disease; Yumanity and Merck Inks $500M Deal; Simcha Raises $25M Visit Post
46 Can Alzheimer's be cured with Marijuana? Visit Post
47 The Question That Remains Unanswered: What Might Be Causing Alzheimer’s? Visit Post
48 Can Aducanumab Slove the Puzzle Of Alzheimer’s? Visit Post
49 When Technological Innovations Help in Remembering for People Living with Alzheimer’s Visit Post
50 Gene-edited T cells for diabetes treatment; Pliant raised $144 million; Accent, AstraZeneca aim RNA modifiers in cancer deal; NodThera Raises $55M; Visit Post
51 What are the 10 early signs of Alzheimer’s that are overlooked? Visit Post
52 An Ageing Population and Upcoming Therapies: What is shaping the Alzheimer’s Disease Market Scenario? Visit Post
53 Startup focuses tumors with CAR-T; AbCellera grabs USD 105M; Gilead inks USD 2B deal; GSK’s anti-BCMA antibody receives a boost Visit Post
54 CanSino deals with Precision; Atea raises USD 215 M; Applied Molecular Transport targets for USD 100 M IPO; Cell therapy repairs multiple sclerosis in mice Visit Post
55 Acquisition of Stemline; Roche’s Elecsys Anti-SARS-CoV-2 antibody test; Newron’s abandonment of STARS trial Visit Post
56 Remdesivir accelerates for COVID-19 recovery; Merck pact with Almac; Pfizer, BioNTech finish dosing in; Taysha Gene Therapies for trials Visit Post
57 AbbVie, Sofinnova back; Gilead, Kite ink; Biogen aims filing; Reversing diabetes Visit Post
58 Parkinson’s Disease Market: Impact of Emerging therapies on Parkinson’s therapeutics market Visit Post
59 Evotec, Vifor Pharma collaborates to cure kidney diseases; AZ takes major steps to advance pharma and medicine R&D in China; Amneal licenses-in a Myasthenia Gravis drug from Kashiv BioSciences Visit Post
60 AZ sells EU rights for Schizophrenia to Cheplapharm; Astellas, Pandion unite to extract the potential of immunomodulation; Pear therapeutics on a journey to develop digital GI treatments with Ironwood Visit Post
61 Biogen seeks the FDA approval to revive its Alzheimer’s drug Aducanumab Visit Post
62 EicOsis receives USD 15M to fuel its non-opioid pain therapy; Alexion Pharmaceuticals buys Achillion Pharmaceuticals; Ipsen adds another drug to its rare disease pipeline Visit Post
63 A New Era for Migraine Treatment and CGRP antibodies Visit Post
64 World Alzheimer’s Day Visit Post
66 Parkinson's Disease: 5 stages, Risk Factors, Prevention, Gene Therapy Visit Post
67 NICE endorsement for Pfizer’s Vizimpro; Eisai, Dundee targets Cancer; Capital raise for AgaMatrix Visit Post
68 Post-Traumatic Stress Disorder Day Visit Post
69 The era of Gene therapy, and the Billion Dollar tag Visit Post
70 World Multiple Sclerosis Day Visit Post
71 Meet the World's most expensive drug: Zolgensma Visit Post
72 Spinal Muscular Atrophy Market Visit Post
73 Spinal Muscular Atrophy: Current and Emerging Therapies Visit Post
74 Parkinson's Awareness Month 2019 Visit Post
75 Spinal Muscular Atrophy Market is expected to augment at a CAGR of 10.42% Visit Post
76 Can Spinal Muscular Atrophy be treated by Protease Inhibitors? Visit Post
77 Notizia Visit Post
78 Global Parkinson’s Therapeutic Market Outlook Visit Post
79 Beta Interferons prolongs life in Multiple Sclerosis Visit Post
80 What can be the scope of Medical Marijuana? Visit Post
81 Notizia Visit Post
82 Alzheimer's drug fails! Is it time to move on? Visit Post
83 Notizia Visit Post
84 Biogen buys Nightstar; Pacira acquires Myoscience; Horizon Pharma announces pricing; STAT with Slingshot Insights; Epizyme announces Equity Offering Visit Post
85 Notizia Visit Post
86 The antidepressant drug gets support from FDA Visit Post
87 Antidepressant of J&J leads to FDA; SCLC model discloses; Genes and macular degeneration can disclose new treatment ways Visit Post
88 Notizia Visit Post
89 Juvenescence raises $46M; Brainsway files for IPO; Life Biosciences raises Visit Post
90 Attention-Deficit/Hyperactivity Disorder (ADHD) Visit Post
91 The lab-grown mini-brains generate electrical patterns Visit Post
92 ‘Invisible’ mice reveal anatomical secrets Visit Post
93 Antidepressants withdrawal hits millions of people Visit Post
94 Notizia Visit Post
95 Voltage-Dependent T-Type Calcium Channel Blockers  Visit Post
96 Biohaven’s trial ; GSK integrates; FDA Approval; Phase III trial Visit Post
97 Novartis ventures; Bill Gates invests; Arcus Biosciences gains; Denali and Odonate seek funding; Fosun Pharma acquires Visit Post
98 Reprogrammed cells relieve Parkinson's symptoms in trials Visit Post
99 Samsung biosim nod sets; Lilly's med hits; BioMarin sees pricing; Spinraza scores; Klick creates Visit Post
100 Biogen triumphs; Lilly, Pfizer, Ipsen back; Court nixes; Mylan EpiPen recall Visit Post
101 Mylan closing Illinois plant; Insys spends $24M; Roche's Ocrevus; Greece’s corruption prosecutor quits Visit Post
102 SEC scrutinizes; Acacia meets endpoint; Axovant's dementia drug; Novartis expands; Aurobindo responds Visit Post
103 NMDA Receptor Antagonist: Emerging therapies in CNS Visit Post
104 Fatal French clinical trial failed to check data before raising dose Visit Post
105 Novartis joins; Sanofi weighs Actelion; Valeant and Takeda's $10B deal; Astellas scouts pipeline Visit Post
106 The Snippet: The Success of Cannabidiol Visit Post
107 Roche's drug; Cancer drugs risk; FDA norms; Takeda sets deal Visit Post
108 Treatment for esophageal cancer; FDA bans soaps; Dr Reddy's Launches; Cipla Gets Approval Visit Post
109 Identity Crises Faced by a Venerable Brain-Cancer Cell Line Visit Post
110 BI & Duke Clinical Research Institute have expansion; BioInvent Inks Mfg. Pact; Elite Pharma, SunGen Pharma in Development & License Deal; Boehringer and Saniona Develop new Compounds; BioLineRx and I-Bridge Capital Establish; Alliance between Harvard and Tata Companies; Innovative Targeting Solutions and Johnson & Johnson Innovation collaborate Visit Post
111 Denali's Impressive Research Portfolio Visit Post
112 NATCO Pharma surges; AstraZeneca falls; US patent office rules Visit Post
113 Fatty Acid Amide Hydrolase (FAAH) Inhibitors - Pipeline Insights, 2015 - A DelveInsight’s Report Visit Post
114 DelveInsight’s Central Nervous System Disorders based Gene Therapy Reports Visit Post
115 Brain Hemorrhage-Pipeline Insights, 2014 Visit Post